LONGEVA.

Tesamorelin: adverse events and evidence limits

The six-month subcutaneous tesamorelin trial in antiretroviral-treated HIV patients with abdominal fat accumulation reported injection-site bruising, paresthesias and serious events in both groups. [1]

This short summary does not estimate event frequencies. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Injection-site bruisingAntiretroviral-treated HIV patients with abdominal fat accumulation, subcutaneous tesamorelin, six monthsReported; this short summary does not estimate event frequencies[1]
ParesthesiasThe same patientsReported; no frequency given[1]
Serious eventsThe same patientsReported in both groups; no frequency given[1]

References

  1. Takara L Stanley et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation. 10.1001/jama.2014.8334.